Mode
Text Size
Log in / Sign up

Pilot retrospective case control study of congenital heart disease in maternal-infant dyads

Pilot retrospective case control study of congenital heart disease in maternal-infant dyads
Photo by Logan Voss / Unsplash
Key Takeaway
Note that this pilot study shows similar maternal and neonatal parameters overall despite small-to-moderate placental differences in preterm cases.

This pilot retrospective case control study investigated placental, neonatal, and maternal parameters in maternal-infant dyads with congenital heart disease (CHD) compared to those without. The study population consisted of n=34 dyads with CHD and n=34 without CHD, sourced from a local biobank setting. Secondary outcomes included birthweight, placental weight, placental efficiency, %FVE, placental vascular index, hypertensive disorders of pregnancy, and gestational diabetes. The authors report that overall placental, neonatal, and maternal parameters were similar between groups, with no significant differences noted in the limitations section.

For preterm neonates, the study observed lower placental weight, %FVE, and placental vascular index, alongside higher placental efficiency. These differences were characterized as having a small-to-moderate effect size. Among term neonates, lower birthweight, placental weight, and placental vascular index were observed, with a moderate effect size suggested for placental vascularization differences. Specific absolute numbers, p-values, or confidence intervals were not reported for these outcomes.

The study acknowledges that differences between groups were not significant in the broader context of the pilot design. Safety data, including adverse events, discontinuations, and tolerability, were not reported. Given the pilot nature of the research and the absence of statistical significance for primary comparisons, the authors caution against overinterpreting the moderate effect sizes regarding placental vascularization in preterm neonates with CHD.

Study Details

Sample sizen = 34
EvidenceLevel 5
PublishedApr 2026
View Original Abstract ↓
Background: Placental function is associated with congenital heart defects (CHD), frequently presenting with malperfusion lesions and small-for-gestational-age size. However, placental villous vasculature in the setting of CHD is understudied. This study evaluated differences in placental, neonatal, and maternal outcomes among maternal/infant dyads with versus without CHD. Methods: We conducted a gestational age- and fetal sex-matched retrospective case control study using specimens prospectively collected by a local biobank. Neonatal outcomes included birthweight, placental weight, and their ratio (placental efficiency). We estimated the proportion of placental villous tissue comprised of fetal vascular endothelial cells (%FVE) using anti-CD34 immunohistochemistry and a pixel count algorithm. Placental weight multiplied by %FVE estimated the grams of placental tissue comprised of villous vasculature (placental vascular index). Maternal outcomes included hypertensive disorders of pregnancy and gestational diabetes. We compared cases and controls using linear and logistic regression adjusted for maternal smoking and cold ischemia time. Stratified analyses examined associations by preterm birth status. Results: Dyads (n=34 with CHD, n=34 without CHD) had maternal age of 29.4 +/- 4.9 years and were 35.6 +/- 4.0 gestational weeks at delivery. Groups had similar placental, neonatal, and maternal parameters. Among preterm neonates, we observed small-to-moderate effect sizes indicating lower placental weight, %FVE, and placental vascular index, and higher placental efficiency, in CHD cases. Among term neonates, moderate effect sizes suggested lower birthweight, placental weight, and placental vascular index in CHD cases. Conclusions: Though differences between groups were not significant, moderate effect sizes suggested that placental vascularization was lower among preterm neonates with CHD.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.